Google
TBPH 株価分析 — Theravance Biopharma Inc (Healthcare >> Biotechnology)
TBPH に関するよくある質問
TBPHのPER（株価収益率）は？
Theravance Biopharma Inc（TBPH）は現在PER 7.32倍で取引されています。
TBPHのROE（自己資本利益率）は？
Theravance Biopharma IncのROEは39.42%です。
TBPHの配当利回りは？
Theravance Biopharma Incの配当利回りは0.00%です。
TBPHの品質スコア（Quality Score）は？
当社のAIはTBPHの総合財務品質を100点中77点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
TBPHは今が買い時ですか？
当社AIのタイミングスコアは100点中67点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
TBPHはどのセクターに属しますか？
Theravance Biopharma IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
TBPH AI Analysis Summary
Our AI summary for TBPH: Theravance Biopharma Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 7.32, ROE of 39.42%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 16.88
Price
0.01
(0.06%)
Day Change
|
|
|---|
TBPH, ファンダメンタルスコアはgood ( ファンダメンタル = 77) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROEの伸びが低い
ROAの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
60% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.13 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
111
|
| Magic Formula Rank by ROE |
111
|
| Magic Formula Rank by ROIC |
104
|
| Price | 16.88 |
| PBV / Sector |
3.01 / 44,022.72
|
| Earning Per Share | 2.21 |
| PE / Sector |
7.32 / 19.17
GREAT
|
| PEG or PE/Growth / Sector |
-0.06 / 1.24
|
| Average 1M Daily Value |
9.36 M
|
| Average 1W Daily Value |
6.83 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
47% |
| ポイントになる統計 |
|
68% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:56 |
| Symbol | TBPH |
| Name | THERAVANCE BIOPHARMA INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 51.83 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 874.34 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080
Phone: 650 808 6000
Website: https://www.theravance.com
Employees: 90
Sector: Healthcare >> Biotechnology
Description: Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
